Two New IPF Treatments Reportedly Will Cost Between $94K ... | 合法藥品大搜索

2014年10月23日—DependingonwhetherornotaprescribingphysicianchoosesRoche'sEsbrietoverOFEV,thechoiceinnotlikelytobemadeovertheirprice ...

The United States just received the first two treatments for idiopathic pulmonary fibrosis[1], however, while Boehringer Ingelheim GmbH[2]‘s therapy, OFEV (nintedanib), will cost $96,000 per year, its competitor, Esbriet (pirfenidone) from InterMune/Roche Holding AG won’t cost much less, according to a news report from Bloomberg[3]. Both therapies recently received approval by the U.S. Food and Drug Administration to help treat the disease, which leads to death of 60 to 80 percent of IPF patients within five years of diagnosis.

Idiopathic pulmonary fibrosis is a chronic disease, and as a result, patients need medication and treatment throughout their lives. Depending on whether or not a prescribing physician chooses Roche’s Esbriet over OFEV, the choice in not likely to be made over their price tags, since the company has announced that t...